Search Clinical Trials

103 Results

Terminated
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (External Link)
Avelumab is a fully human monoclonal PD-L1 antibody of the immunoglobulin G1 (IgG1) subclass. It works by binding to PD-L1 on tumor cells, immune cells and/or stromal cells. This prevents …
Baylor Role: Lead Sponsor
Completed
N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy (External Link)
Biliary atresia (BA) is a disease characterized by fibro-obliteration of extrahepatic bile ducts leading to impaired bile flow (Sokol et al., 2007). BA is treated with the Kasai portoenterostomy (KP), …
Baylor Role: Lead Sponsor
Recruiting
Glutathione in Mild Cognitive Impairment (External Link)
Subjects with MCI will be recruited by written informed consent using forms approved by the Baylor IRB. Subjects will stop nonvitamin supplements for 4wks before screening labs (blood count, HbA1c, …
Baylor Role: Lead Sponsor
Completed
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta (External Link)
Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in …
Baylor Role: Lead Sponsor
Recruiting
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (External Link)
To make the T cells the investigators will take blood from the patient or from the previous bone marrow transplant donor and stimulate it with growth factors to make the …
Baylor Role: Lead Sponsor
Terminated
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM (External Link)
TREATMENT PLAN PREOPERATIVE HYDRATION According to our observations, preoperative hydration reduces the risk of nephrotoxicity from intrathoracic infusion of hyperthermic cisplatin. Therefore, all patients will be admitted the night before …
Baylor Role: Lead Sponsor
Completed
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma (External Link)
Subjects with MPM will undergo surgical mediastinal lymph node biopsy (cervical mediastinoscopy) and simultaneous surgical biopsy of the pleural tumor by thoracoscopy, at which time tumor tissue (at least 2 …
Baylor Role: Lead Sponsor
Completed
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (External Link)
The investigators will draw blood from the subject to make EBV-specific cytotoxic T-lymphocytes (EBVSTs) in the lab. Investigators will make the cells by first growing a special type of cells …
Baylor Role: Lead Sponsor
Completed
Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders (External Link)
The standard of care in patients receiving rituximab is to give the dose slowly and gradually increase the rate of rituximab until the full dose is given, which may take …
Baylor Role: Lead Sponsor
Withdrawn
Acthar on Proteinuria in IgA Nephropathy Patients (External Link)
Participation in this study may last up to 2 years (from first visit to final visit) and includes 10 study visits and 8 phone calls. Subjects will be randomly assigned …
Baylor Role: Lead Sponsor